• Explore /
  • Poster
  • / NSAB C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.

NSAB C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.

Abstract Poster

Authors

Mohamed Salem

Mohamed E. Salem

Levine Cancer Institute, Atrium Health, Charlotte, NC

Mohamed E. Salem , Shannon Leigh Huggins-Puhalla , Thomas J. George , Carmen Joseph Allegra , Melanie R. Palomares , Frederick L Baehner , Norman Wolmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

05210283

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3632)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3632

Abstract #

TPS3632

Poster Bd #

424a

Abstract Disclosures

Similar Posters

First Author: Mohamed E. Salem

First Author: Yoshiaki Nakamura

First Author: Yuichiro Tsukada

First Author: Giulia Maddalena